MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$3,040K
Net Income
-$49,013K
Net Profit Margin
-1612.27%
EPS
-$0.4
Unit: Thousand (K) dollars
Revenue Breakdown
Supply revenue
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
3,040
32
348
19,145
Research and development expenses
38,009
38,594
30,971
27,516
Selling, general and administrative expenses
23,451
27,418
24,520
27,264
Total operating expenses
61,460
66,012
55,491
54,780
Operating loss
-58,420
-65,980
-55,143
-35,635
Interest income
5,650
6,473
6,713
7,055
Fair value change - earnout
-
-1
-
-
Fair value change - warrants
-5,942
15,335
23,792
-2,590
Loss on disposal of property, plant and equipment
-
-
-1
-
Foreign exchange losss/(gaines)
-1,613
-82
218
8,626
Loss before tax
-48,441
-74,923
-72,005
-17,364
Loss for the year
-48,441
-74,923
-72,005
-17,364
Unrealized gain/(loss) on available-for-sale securities, net of tax
-572
153
313
-107
Total comprehensive loss for the year, net of tax
-49,013
-74,770
-71,692
-17,471
Basic EPS
-0.4
-0.623
-0.61
-0.15
Diluted EPS
-0.4
-0.623
-0.61
-0.15
Basic Average Shares
121,716,006
120,015,225
119,000,266
118,556,492
Diluted Average Shares
121,716,006
120,015,225
119,000,266
118,556,492
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Total comprehensive
loss for the year, net...
-$49,013K
(-23.90%↓ Y/Y)
Loss for the year
-$48,441K
(-22.55%↓ Y/Y)
Unrealized gain/(loss) on
available-for-sale securities, net...
-$572K
(-1633.33%↓ Y/Y)
Loss before tax
-$48,441K
(-22.55%↓ Y/Y)
Fair value change -
warrants
-$5,942K
(56.82%↑ Y/Y)
Interest income
$5,650K
(-23.14%↓ Y/Y)
Supply revenue
$3,040K
Operating loss
-$58,420K
(15.24%↑ Y/Y)
Revenue
$3,040K
(2.08%↑ Y/Y)
Foreign exchange
losss/(gaines)
-$1,613K
(-137.57%↓ Y/Y)
Total operating
expenses
$61,460K
(-14.52%↓ Y/Y)
Research and development
expenses
$38,009K
(-15.07%↓ Y/Y)
Selling, general and
administrative expenses
$23,451K
(-13.63%↓ Y/Y)
Buy us a coffee
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)